156 related articles for article (PubMed ID: 23955491)
1. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
Zhou B; Yuan F; He Z; Tan C
Brain Imaging Behav; 2014 Mar; 8(1):97-101. PubMed ID: 23955491
[TBL] [Abstract][Full Text] [Related]
2. Detection and application of neurochemical profile by multiple regional
Guan J; Rong Y; Wen Y; Wu H; Qin H; Zhang Q; Chen W
Brain Behav; 2017 Sep; 7(9):e00792. PubMed ID: 28948086
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Hou Z; Zhang Z; Meng H; Lin X; Sun B; Lei H; Fang K; Fang F; Liu M; Liu S
Int J Neurosci; 2014 Feb; 124(2):125-32. PubMed ID: 23931110
[TBL] [Abstract][Full Text] [Related]
4. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
Baik HM; Choe BY; Son BC; Jeun SS; Kim MC; Lee KS; Kim BS; Lee JM; Lee HK; Suh TS
Eur J Radiol; 2003 Sep; 47(3):179-87. PubMed ID: 12927660
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Braak staging of brain pathology with
Cao H; Shi J; Cao B; Kang B; Zhang M; Qu Q
Neurosci Lett; 2017 Nov; 660():57-62. PubMed ID: 28844732
[TBL] [Abstract][Full Text] [Related]
6. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
[TBL] [Abstract][Full Text] [Related]
7. Metabolic alterations in Parkinson's disease after thalamotomy, as revealed by 1H MR spectroscopy.
Baik HM; Choe BY; Lee HK; Suh TS; Son BC; Lee JM
Korean J Radiol; 2002; 3(3):180-8. PubMed ID: 12271163
[TBL] [Abstract][Full Text] [Related]
8. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
Nie K; Zhang Y; Huang B; Wang L; Zhao J; Huang Z; Gan R; Wang L
Parkinsonism Relat Disord; 2013 Mar; 19(3):329-34. PubMed ID: 23238068
[TBL] [Abstract][Full Text] [Related]
9. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
10. Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.
Wu G; Shen YJ; Huang MH; Xing Z; Liu Y; Chen J
AJR Am J Roentgenol; 2016 Feb; 206(2):385-9. PubMed ID: 26797368
[TBL] [Abstract][Full Text] [Related]
11. Temporal pole proton preoperative magnetic resonance spectroscopy in patients undergoing surgery for mesial temporal sclerosis.
Fountas KN; Tsougos I; Gotsis ED; Giannakodimos S; Smith JR; Kapsalaki EZ
Neurosurg Focus; 2012 Mar; 32(3):E3. PubMed ID: 22380857
[TBL] [Abstract][Full Text] [Related]
12. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR
Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574
[TBL] [Abstract][Full Text] [Related]
13. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U
Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082
[TBL] [Abstract][Full Text] [Related]
14. The usage of proton magnetic resonance spectroscopy in Parkinson's disease.
Metarugcheep P; Hanchaiphiboolkul S; Viriyavejakul A; Chanyawattiwongs S
J Med Assoc Thai; 2012 Jul; 95(7):949-52. PubMed ID: 22919991
[TBL] [Abstract][Full Text] [Related]
15. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy.
Choe BY; Park JW; Lee KS; Son BC; Kim MC; Kim BS; Suh TS; Lee HK; Shinn KS
Invest Radiol; 1998 Aug; 33(8):450-5. PubMed ID: 9704284
[TBL] [Abstract][Full Text] [Related]
16. The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes.
Zanigni S; Testa C; Calandra-Buonaura G; Sambati L; Guarino M; Gabellini A; Evangelisti S; Cortelli P; Lodi R; Tonon C
Parkinsonism Relat Disord; 2015 Aug; 21(8):929-37. PubMed ID: 26077167
[TBL] [Abstract][Full Text] [Related]
17. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
18. [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Aotsuka A; Shinotoh H; Hattori T
Nihon Rinsho; 1997 Jan; 55(1):249-54. PubMed ID: 9014459
[TBL] [Abstract][Full Text] [Related]
19. Proton magnetic resonance spectroscopy for radiation encephalopathy induced by radiotherapy for nasopharyngeal carcinoma.
Qiu SJ; Zhang XL; Zhang Y; Jiang M
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):241-6. PubMed ID: 17425962
[TBL] [Abstract][Full Text] [Related]
20. Thalamic neurometabolic alterations in tremulous Parkinson's disease: A preliminary proton MR spectroscopy study.
Barbagallo G; Arabia G; Morelli M; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A; Caracciolo M; Sabatini U; Cherubini A; Quattrone A
Parkinsonism Relat Disord; 2017 Oct; 43():78-84. PubMed ID: 28774469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
